MTHFR C677T polymorphism and ovarian cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3937-3942

  Ding, Xiao Ping ^a   Feng, Li ^a   Ma, Li ^a  

^a The Second Artillery General Hospital   (China)

Author keywords

Meta analysis; Mthfr; Ovarian cancer; Polymorphism

Indexed keywords

EID: 84873635486     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3937     Document Type: Article

References (43)

1. Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol, 56, 297-303.
2. Bhopal R (2004). Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health, 58, 441-5.
3. Bhurgri Y, Shaheen Y, Kayani N, et al (2011). Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev, 12, 1567-71.
4. Burchard EG, Ziv E, Coyle N, et al (2003). The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med, 348, 1170-5.
5. Cannistra SA (2004). Cancer of the ovary. N Engl J Med, 351, 2519-29.
6. Clarke-Pearson DL (2009). Clinical practice. Screening for ovarian cancer. N Engl J Med, 361, 170-7.
7. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
9. Diaz-Padilla I, Amir E, Marsh S, et al (2012). Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol, 124, 354-65.
10. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36.
11. Dong X, Wu J, Liang P, et al (2010). Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res, 41, 125-33.
12. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
13. Frosst P, Blom HJ, Milos R, et al (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, 111-3.
14. Gao S, Liu N, Ma Y, et al (2012). Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk. Asian Pac J Cancer Prev, 13, 569-73.
15. Gershoni-Baruch R, Dagan E, Israeli D, et al (2000). Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer, 36, 2313-6.
16. Goyette P, Sumner JS, Milos R, et al (1994). Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet, 7, 195-200.
17. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
18. Holmes MV, Newcombe P, Hubacek JA, et al (2011). Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet, 378, 584-94.
19. Huang M, Chen Q, Xiao J, et al (2012). CYP1A1 Ile(462)Val is a risk factor for ovarian cancer development. Cytokine, 58, 73-8.
20. Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335, 914-6.
21. Jakubowska A, Gronwald J, Menkiszak J, et al (2007). Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat, 104, 299-308.
22. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
23. Jin F, Qu LS, Shen XZ (2009). Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn Pathol, 4, 39.
24. Khanra K, Panda K, Bhattacharya C, et al (2012). Association of two polymorphisms of DNA polymerase Beta in exon-9 and exon-11 with ovarian carcinoma in India. Asian Pac J Cancer Prev, 13, 1321-4.
25. Kim YI (2005). 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev, 63, 398-407.
26. Kiyohara C, Horiuchi T, Takayama K, et al (2011). Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population. BMC Cancer, 11, 459.
27. Magnowski P, Seremak-Mrozikiewicz A, Nowak-Markwitz E, et al (2010). [No association between MTHFR 677C>T polymorphism and ovarian cancer risk in BRCA1 mutation carriers in Wielkopolska region]. Ginekol Pol, 81, 506-10.
28. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
29. Pawlik P, Mostowska A, Lianeri M, et al (2011). Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep, 39, 5553-60.
30. Pennington KP, Swisher EM (2012). Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol, 124, 347-53.
31. Petitti DB. (2000) Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nded). New York, NY: Oxford University Press.
32. Prasad VV, Wilkhoo H (2011). Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie, 34, 422-6.
33. Salanti G, Amountza G, Ntzani EE, et al (2005). Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet, 13, 840-8.
34. Sharp L, Little J (2004). Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol, 159, 423-43.
35. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469.
36. Taioli E, Garza MA, Ahn YO, et al (2009). Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol, 170, 1207-21.
37. Terry KL, Tworoger SS, Goode EL, et al (2010). MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol Oncol, 119, 319-24.
38. T hompson SG, Higgins J (2002). How should meta, regression analyses be undertaken and interpreted? Stat Med, 21, 1559-73.
39. Tobias A (1999). Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull, 8, 15-7.
40. W ebb PM, Ibiebele TI, Hughes MC, et al (2011). Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer. Eur J Clin Nutr, 65, 1133-40.
41. Wu Y, Zhang JY, Zuo WJ (2007). Association between genetic polymorphisms of methylenetetrahydrofolate reductase C677T and susceptibility to ovarian cancer. Xian Dai Fu Chan Ke Jin Zhan, 16, 811-3.
42. Zhang J, Qiu LX, Wang ZH, et al (2010). MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls. Breast Cancer Res Treat, 123, 549-55.
43. Zhang Y, Chen GQ, Ji Y, et al (2012). Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep, 39, 6203-11.